التجارب السريرية بالأسفل التجارب السريرية الحالية.537 دراسات في علم الأورام (طبي) (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy Jacksonville, Fla. The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS). Understanding the Patient Experience in Progesterone Management for Endometrial Cancer and Complex Atypical Hyperplasia Rochester, Minn. The purpose of this study is to gain a deeper understanding of the specific patient experience for women undergoing progesterone management for early-stage endometrial cancer and complex atypical hyperplasia due to morbid obesity (BMI ≥ 40). MElanoma Research Lymph node prediction Implementation National_001 (MERLIN_001) Rochester, Minn. This study aims to create a registry for primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Eau Claire, Wis., Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to assess how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone. Interviews About Social Determinants of Health in Southeast Asian Americans to Identify Liver Cancer Disparities Rochester, Minn. This study is intended to understand the experiences and barriers to cancer care for individuals diagnosed with liver or any other type of cancer. Individual interviews will be conducted. Trial of Multi-epitope HER2 Peptide Vaccine in Patients with HER2-expressing DCIS Rochester, Minn., Jacksonville, Fla. The purpose of this study is to determine the safety, effcicacy and tolerability of H2NVAC in patients with HER2-expressing DCIS in order to prevent future invasive breast cancer among patients who are diagnosed with DCIS. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. The purpose of this study is to evaluate olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that has spread to other places of the body or cannot be removed by surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib and temozolomide may work better than giving either drug alone in treating patients with LMS. Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy Rochester, Minn. The purpose of this study is: To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review. To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Rochester, Minn., Jacksonville, Fla. The purpose of this study is to evaluate the effects of ibrutinib and rituximab with or without venetoclax in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously untreated Waldenstrom's macroglobulinemia than ibrutinib and rituximab alone. A Study of a New Molecular Approach to Blood DNA Screening for Cancer Rochester, Minn. The primary aim of this study is to evaluate the distribution of marker levels determined by this multi-marker, multi-compartment blood DNA test approach across persons without known cancer or precancer. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 1111 توجّه للصفحة 1212 توجّه للصفحة 1313 توجّه للصفحة 1414 توجّه للصفحة 1515 التاليالصفحة التالية طلب تحديد موعد الخبرة و مراتب التصنيفبحث 09/05/2023 صنَّفت شبكة U.S. News & World Report مستشفيات مايو كلينك في مدينة روتشستر بولاية مينيسوتا وفي مدينة جاكسونفيل بولاية فلوريدا وفي مدينتيّ فينيكس/سكوتسديل بولاية أريزونا ضمن أفضل مستشفيات علاج السرطان في الولايات المتحدة لعام 2023-2024. اعرف المزيد عن هذا الشرف الرفيع علم الأورام (طبي)القسمالرئيسيالأقساممُلخّصالحالات التي تم علاجهاالأطباءالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب موعدمُلخّصالحالات التي تم علاجهاالأطباءالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالة المرضى ORG-20180179 الأقسام والمراكز الطبية علم الأورام (طبي)